OnCo

Sign in to keep your watchlist

Your watched pages live in this browser. Sign in with an email link and OnCo keeps the same list on every device you use. Only your email address and your watchlist are stored.

Living with cancer·Standard of care

Lower-risk myelodysplastic syndromes: the decisions you may face

Cancer page →Second-opinion finder →

4 treatment settings, 3 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Other settings

Asymptomatic, no transfusions

One path named

Observation with blood counts every three to six months; no treatment.

Guideline
NCCN Guidelines: Myelodysplastic Syndromes
The path, in plain words
Transfusion support and anaemia managementStandard of care

Red cell and platelet transfusions, iron and erythropoiesis-stimulating agents keep patients safe through chemotherapy and marrow failure; restrictive thresholds and ESA caution reflect trials showing more is not better.

  • Life-saving in acute leukaemia and transplant
  • Restrictive strategies proven safe and cheaper
  • New MDS agents reduce transfusion burden
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
Transfusion support and anaemia management
  • Blood supply shortages, especially in LMICs
  • ESA safety restricts use
  • Iron overload and alloimmunisation with chronic transfusion
Questions to ask about this decision
  1. Is Transfusion support and anaemia management the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
    Why: A single standard does not mean a single choice; timing and trials are decisions too.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (NCCN Guidelines: Myelodysplastic Syndromes), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (asymptomatic, no transfusions), which of the standard options do you recommend and why?
    Why: Guideline options include: Observation with blood counts every three to six months; no treatment.

Add these to your appointment list, or take the full question set for this cancer.

Advanced, first line

Anaemia, first line

4 optionsCompare side by side →

Luspatercept for ring-sideroblast or SF3B1-mutated disease and for transfusion-dependent patients (COMMANDS); erythropoiesis-stimulating agent where serum erythropoietin is below 500 U/L; lenalidomide for del(5q).

Guideline
NCCN Guidelines: Myelodysplastic Syndromes
The options, in plain words
LuspaterceptApprovedErythroid maturation agent (activin receptor IIB ligand trap, Fc fusion)

An injection that helps the marrow finish making red cells, reducing or removing the need for transfusions in lower-risk MDS and beta-thalassaemia.

Epoetin alfaApprovedRecombinant erythropoietin (erythropoiesis-stimulating agent)

Epoetin alfa is a manufactured version of the kidney hormone that tells the bone marrow to make red blood cells. In cancer it treats anaemia caused by chemotherapy and reduces the need for transfusions, but it is used cautiously because it can shorten survival and cause clots.

Darbepoetin alfaApprovedHyperglycosylated recombinant erythropoietin (erythropoiesis-stimulating agent)

Darbepoetin alfa (Aranesp) is a longer-acting version of erythropoietin given every one to three weeks to treat anaemia caused by chemotherapy, reducing transfusions but with the same warnings about clots and tumour growth as epoetin.

LenalidomideApprovedImmunomodulatory drug (cereblon E3 ligase modulator)

Lenalidomide is a thalidomide descendant that glues the proteins IKZF1 and IKZF3 to cereblon so the cell destroys them, killing plasma cells and rousing T cells. It is the backbone of myeloma treatment and maintenance, also used in mantle cell and follicular lymphoma, and generic since 2022.

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
Lenalidomideall recorded rates →
  • Dose by creatinine clearance: 10 mg daily for CrCl 30-60, 15 mg every other day below 30, 5 mg daily on dialysis.
Questions to ask about this decision
  1. Between Luspatercept, Epoetin alfa, Darbepoetin alfa and the other options, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (NCCN Guidelines: Myelodysplastic Syndromes), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (anaemia, first line), which of the standard options do you recommend and why?
    Why: Guideline options include: Luspatercept for ring-sideroblast or SF3B1-mutated disease and for transfusion-dependent patients (COMMANDS); erythropoiesis-stimulating agent where serum erythropoietin is below 500 U/L; lenalidomide for del(5q).
  6. Am I a candidate for Luspatercept, Epoetin alfa, Darbepoetin alfa or related drugs, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Anaemia after erythropoietin or luspatercept failure

3 optionsCompare side by side →

Imetelstat (IMerge); luspatercept if not yet used; low-dose hypomethylating agent; trials of elritercept and other agents.

Guideline
NCCN Guidelines: Myelodysplastic Syndromes
The options, in plain words
ImetelstatApprovedTelomerase inhibitor (oligonucleotide)

Imetelstat is a lipid-linked oligonucleotide that binds the RNA template of telomerase, the enzyme cancer cells use to stay immortal, and it is the first telomerase inhibitor approved for any cancer. In lower-risk myelodysplastic syndromes it freed 40% of transfusion-dependent patients from transfusions for at least eight weeks versus 15% on placebo, once growth factors have failed.

LuspaterceptApprovedErythroid maturation agent (activin receptor IIB ligand trap, Fc fusion)

An injection that helps the marrow finish making red cells, reducing or removing the need for transfusions in lower-risk MDS and beta-thalassaemia.

AzacitidineApprovedSmall-molecule hypomethylating agent (cytotoxic)

A gentle chemotherapy that switches silenced genes back on. With venetoclax it became the standard for older people with AML who cannot take intensive treatment.

The evidence behind it
The main trade-offs on record
Azacitidineall recorded rates →
Side effectAny gradeGrade 3+
Neutropenia · VIALE-A combination arm-42%

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

Questions to ask about this decision
  1. Between Imetelstat, Luspatercept and Azacitidine, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. How closely do I match the people in A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B and Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS), and does that change what the results mean for me?
    Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
  4. Which side effects of Azacitidine are most likely for me, which are reversible, and which would make us stop?
    Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
  5. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  6. Does your recommendation follow the current guideline (NCCN Guidelines: Myelodysplastic Syndromes), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  7. For my situation (anaemia after erythropoietin or luspatercept failure), which of the standard options do you recommend and why?
    Why: Guideline options include: Imetelstat (IMerge); luspatercept if not yet used; low-dose hypomethylating agent; trials of elritercept and other agents.
  8. Am I a candidate for Imetelstat, Luspatercept, Azacitidine, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
  9. How do the results of A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B and Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) apply to someone like me?
    Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

Special situations

Supportive care

2 options

Red cell transfusion to symptoms, iron chelation once ferritin is persistently high, G-CSF for recurrent neutropenic infection, platelet transfusion for bleeding.

Guideline
NCCN Guidelines: Myelodysplastic Syndromes
The options, in plain words
Transfusion support and anaemia managementStandard of care

Red cell and platelet transfusions, iron and erythropoiesis-stimulating agents keep patients safe through chemotherapy and marrow failure; restrictive thresholds and ESA caution reflect trials showing more is not better.

  • Life-saving in acute leukaemia and transplant
  • Restrictive strategies proven safe and cheaper
  • New MDS agents reduce transfusion burden
Growth factors: G-CSF and febrile neutropenia preventionStandard of care

Injections of filgrastim or its long-acting form pegfilgrastim after chemotherapy make white cells recover faster, cutting the risk of life-threatening infections and allowing chemotherapy on schedule.

  • Halves febrile neutropenia; maintains dose intensity
  • Biosimilars widely available
  • Enables dose-dense regimens (e.g. every-2-week AC-T)
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
Transfusion support and anaemia management
  • Blood supply shortages, especially in LMICs
  • ESA safety restricts use
  • Iron overload and alloimmunisation with chronic transfusion
Growth factors: G-CSF and febrile neutropenia prevention
  • Bone pain in ~30%
  • Cost drove over- and under-use
  • Rare splenic rupture; theoretical MDS/AML risk debated
Questions to ask about this decision
  1. Between Transfusion support and anaemia management and Growth factors: G-CSF and febrile neutropenia prevention, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (NCCN Guidelines: Myelodysplastic Syndromes), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (supportive care), which of the standard options do you recommend and why?
    Why: Guideline options include: Red cell transfusion to symptoms, iron chelation once ferritin is persistently high, G-CSF for recurrent neutropenic infection, platelet transfusion for bleeding.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.